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Tyrosine kinase inhibitors (TKIs) are new generation of anti-cancer drugs with 
very high efficiency against cancer cells. However, TKIs are associated with severe 
cardiotoxicity limiting their clinical benefits. One particular TKI that has been 
developed recently but not explored much is Ponatinib. The use of nanoparticles as a 
better therapeutic agent to deliver anti-cancer drugs and reduce their cardiotoxicity has 
been recently considered. In this study, PLGA-PEG-PLGA nanoparticles were 
synthesized to deliver Ponatinib while reducing its cardiotoxicity for treatment of 
chronic myeloid leukemia. Shape, size, surface charge and drug uptake ability of these 
nanoparticles were assessed using transmission electron microscopy (TEM), 
ZetaSIZER NANO and high-performance liquid chromatography (HPLC). 
Cardiotoxicity of Ponatinib, unloaded and loaded PLGA-PEG-PLGA nanoparticles 
were studied on zebrafish model through measuring the survival rate and cardiac 
function parameters, to optimize efficient drug concentrations in an in vivo setting. 
These particles were tested on zebrafish cancer xenograft model in which, K562 cell 
line, was transplanted into zebrafish embryos. We showed that, at an optimal 
concentration (0.0025mg/ml), Ponatinib loaded PLGA-PEG-PLGA particles are non-
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Chapter 1: Introduction 
1.1 Introduction 
Cancer is the second leading cause of death worldwide with high number of incidents 
[1]. Cancer arises from mutations that cause activation of oncogenes or/and inactivation of the 
tumor suppressor genes leading to uncontrolled cell growth and proliferation, which further 
trigger other complications in the body that eventually might lead to death [2]. Leukemia is a 
type of cancer that is characterized by the uncontrolled growth of the hematopoietic stem cells 
from the bone marrow [3]. There are several subtypes of leukemia and the most encountered 
subtype among adults is the Chronic Myeloid leukemia (CML) [3]. CML is generally 
diagnosed by the presence of the Philadelphia chromosome that harbor the BCR-ABL 
oncogene, which would cause abnormal cell proliferation and complications in the patients [4].  
Therefore, the demand for successful anti-cancer therapeutics and developing of 
effective tools for early cancer detection and screening have been increased. For example, the 
evolving of the Tyrosine Kinase inhibitors (TKIs) [5] such as, Imatinib, Nilotinib, Ponatinib 
and Dasatinib as anti-cancer drugs particularly for CML had aid in improving the overall 
outcomes of the patients and increasing their survival rates [6]. However, due to some 
encountered toxicity of these drugs especially in the heart [7], the usage of nanotechnology to 
treat the cancer has been raised. This is because nanoparticles (NPs) are known to be more 
effective and precise in targeting cancer cells and reduce toxicity associated with the anti-
cancer drugs [8]. 
zebrafish have been used as a research model in many applications such as, in cancer 
studies due to their numerous advantages. For example, they have high genetic resemblance to 
humans with about 70% orthologue genes, making it a useful model for genetic manipulation 
[9]. Moreover, they are easy to maintain, have short maturation and developing time and the 
transparent embryos have made imaging and studying the internal organs such as the heart 
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much easier [10]. In addition, due to their lack of adaptive immunity during the first months of 
development,  zebrafish is a good model for xenotransplantation of human tumor cells in order 
to develop a cancer model to study human cancers and testing of the anti-cancer drugs [11]. 
1.2 Hypothesis:  
Delivery of Ponatinib, a TKI drug, using smart NPs into CML cells increases the anti-
cancer activity and reduces cardiotoxicity in the zebrafish xenograft model in 
comparing with the use of TKIs drugs alone. 
1.3 Objectives:  
§ To produce smart nanoparticles (PLGA-PEG-PLGA) and define their characteristics.  
§ To generate a zebrafish xenograft model of CML cancer. 
§ To test for the toxicity of TKIs and the generated NPs on normal zebrafish.  
§ To determine the efficacy of the generated NPs as effective anti-cancer drug delivery 
system by testing them on the zebrafish xenograft model.
 
 3 
Chapter 2: Literature Review 
2.1 Cancer 
Cancer is the second main cause of death worldwide after the cardiovascular disease 
[1] with increasing incidences and death rates worldwide throughout the years [12]. Cancer is 
described as uncontrolled cell growth that gains metastatic properties in response to the 
activation of oncogenes and/or deactivation of the tumor suppressor genes [2].   
2.1.1 Prevalence of cancer  
According to the GLOBOCAN (2018), the estimated number of the new cancer cases 
had reached to 18.1 million and the deaths are about 9.6 million [13] and by the year 2030 it 
has been estimated that the cancer death count would reach to 30 million per year [14]. 
Therefore, new tools for early detection and diagnosis of cancer are essential as well as 
developing effective therapeutic agents for cancer treatment such as, nanotechnology are the 
key to reduce cancer mortality and incidences [15]. In Qatar, the overall incidence rate in 2014 
was 66.02 per 100,000 and the most common cancers among the population were beast, 
colorectal and prostate cancers and the burden of cancer is estimated to increase more by 2030 
[16]. Leukemia is also one of the major cancers in Qatar with an incidence of 8.5 per 100,000 
and 4.8 per 100,00 for males and females, respectively [17]. 
2.1.2 Chronic Myeloid Leukemia  
Leukemia is a common malignancy in pediatrics and adults that arises from alternations 
in cell regulatory processes to cause unregulated proliferation of the hematopoietic stem cells 
of the bone marrow leading to the development of different subtypes of leukemia with different 
characteristics such as acute myelogenous, chronic myelogenous, acute lymphoblastic and 
chronic lymphoblastic leukemia and the most common leukemia that almost exclusively occurs 
in adults is the chronic myeloid leukemia [3]. Chronic myeloid leukemia (CML) is a 
myeloproliferative neoplasm that is characterized by the excessive number of granulocytes, 
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which are neutrophils, eosinophils and basophils and it is also known as a clonal disorder of 
the hematopoietic stem cells of the bone marrow [4]. The incidence of  CML is 1-2 cases per 
100,000 adults and about 15% of the newly diagnosed cases of leukemia in adults accounts for 
CML [18]. CML is diagnosed genetically by the presence of the abnormal chromosome, the 
Philadelphia chromosome [4]. Philadelphia chromosome is formed by the oncogene BCR-ABL 
fusion, in which the 3’ portion of the Abelson (ABL) gene on the long arm of chromosome 9 
is combined with the 5’ portion of the breakpoint cluster region (BCR) gene located on the 
long arm of chromosome 22 [4]. The BCR-ABL fusion oncogene is associated with irregular 
proliferation of the myeloid cells, cytogenetic abnormalities as the disease proliferate and 
treatment resistance in case of mutations in the BCR-ABL kinase domain [4]. As, the 
constitutively active tyrosine kinase BCR-ABL would promote growth and proliferation by the 
downstream signaling pathways such as, JUN kinase, STAT and RAS [19-21]. There are three 
phases of CML, chronic, accelerated and blast phases [4].  
2.2 Smart Nanoparticles 
Nanoparticles (NPs) are small particles with a size range from 1 to 1000 nm [22] that 
can be engineered to gain unique compositions and functions in order to be used as tools in 
research areas [23]. NPs come in several types of different sizes, structures and functions, 
which can then be classified accordingly. For instance, they can be categorized based on their 
material type into: 1. carbon-based nanoparticles, in which the particles contain carbon such 
as, graphene (Gr) and carbon black [24]; 2. Inorganic-based nanoparticles, the particles made 
of metals (Au or AG) or metal oxides (TiO2 or ZnO) or from semiconductors (Ceramics or 
Silicon); 3. Organic-based nanoparticles, where the particles are from organic materials that 
transformed into unique structures such as, liposomes, micelles and polymers; 4. Composite-
based nanoparticles are NPs that combine multiple other NPs or materials [25].  
2.2.1 Applications of Nanoparticles 
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NPs have been utilized in many research and biomedical purposes due to their several 
advantages. To illustrate this, NPs can be used as sensors and pathogen detector, using surface 
ligands to amplify the detection and specific binding of the analytes [23] and the most used 
type of NP biosensors  are the inorganic NPs, particularly the metallic or magnetic NPs [26]. 
Also, NPs are used to detect pathogens as bacteria throughout magnetic NPs that are coated 
with antibodies against the bacterial surface antigens [27]. NPs also work as sensitive tools for 
specific cell detection and separation [23]. For example,  circulating tumor cells (CTCs), act as 
biomarkers to determine the prognosis and overall survival levels in metastatic colorectal, 
prostate and breast cancers’ patients [28, 29], are identified and captured through the NP 
immunomagnetic technique [30]. In addition, NPs are promising tools to attribute in targeted 
imagining, because of their surface area they could deliver large number of imaging agents at 
a time, thus enhancing the sensitivity [31]. Lastly, the NPs can also work as delivery vehicles 
to facilitate the entry of some agents into the cells such as, the entrance of the Small interfering 
RNA (siRNA) into the cells allowing it to splice and degrade the mRNA for gene function 
studies [32]. NPs as delivery vehicles can also aid in carrying agents such as drugs to treat 
various diseases for example, diabetes, neurological disorders and cancer [33]; this is due to 
their ability to protect the load from getting degraded and in controlling the drug release by 
improving drug’s accumulation in diseased tissue and decreasing its clearance, therefore the 
therapeutic efficacy would increase and drug side effects would be reduced [34]. 
2.2.2 Nanoparticles in cancer 
Over the past several decades, nanotechnology has made critical contribution in cancer 
studies [35] as it helped in early diagnosis of several cancers such as breast and colorectal 
cancers, through enhancing the imaging and screening techniques and hence improving the 
outcomes of the patients [36]. Moreover, NPs are also applied as effective therapeutic agents 
for cancer treatments due to their ability of targeted delivery, drug storage, tumor imaging and 
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overcoming resistibility, solubility and stability problems [8].  The first type of therapeutic NPs 
to receive clinical approval for cancer treatment is the Liposomes [37] e.g. Daunoxome and 
Doxil that are effective in treating breast and ovarian cancers [38]. 
2.2.3 Toxicity of Nanoparticles  
 The toxicity of the nanomaterials could be seen at different levels i.e., on the molecular, 
cellular as well as on the tissue level [34]. This is due to the ability of those particles to move 
easily through the body, and getting exposed to several biological microenvironments such as, 
the body fluids (e.g., blood), the extracellular matrix, the cytoplasm and to the cell organelles 
[34].   
 To illustrate that, the iron oxide nanoparticles have been reported to cause effects on 
the molecular level by irreversibly changing the structure and function of the transferrin protein 
upon its binding to the particles leading to a permanently damage in the iron transport [39]. 
Also, NPs have been shown to affect the folding ability of fibrinogen that stimulates the 
inflammatory signaling pathways [40].  
 The cellular toxicity of the NPs could be illustrated by the ability of some NPs such as, 
zinc oxide [41], polycation particles [42], titanium oxide [43] and polystyrene nanoparticles 
[44] to disrupt the cell lysosome membrane. Consequently, this would cause the release of iron, 
protons and hydrolytic enzymes that results in protein aggregation, oxidative stress, 
mitochondrial dysfunction and endoplasmic reticulum (ER) stress [45].  
 Moreover, NPs have the ability to cause toxicity on the tissue level especially on the 
organs with the highest NP accumulation level such as the liver after intravenous injection and 
the lung after intratracheal installation [34]. For example, hepatotoxicity has been reported by 
the presence of high levels of the liver enzymes in the blood after administrating positively 
charged lipid nanoparticles [46].   
 Exposure to nanoparticles have also studied to cause cardiac toxicity and subsequently 
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myocardial damage as a result of increased production of reactive oxygen species (ROS) and 
redox homeostasis alternation [47]. For instance, following to the exposure of titanium dioxide 
(TiO2) NPs has showed to increase ROS levels, reduced malondialdehyde and increased the 
DNA peroxidation in the cardiac muscles. While long exposure to TiO2 NPs has resulted into 
sparse cardiac muscle fibers, cardiac biochemical derangement, tissue inflammatory response 
and cell necrosis [48]. Moreover, toxicities associated with zinc oxide (ZnO) NPs have also 
been reported after testing these NPs on a rat animal model [49]. The toxicity was seen as an 
inflammation in the lung tissues and a myocardial damage after exposing the rats for a long 
period of time to ZnO NPs [49]. Also, oral administration of ZnO NPs by the rats showed to 
cause inflammation, DNA damage and apoptosis in the rats’ hearts as well as for the high levels 
of cardiac biomarkers such as troponin T, CPK-MB and myoglobin, that have been detected in 
the rats [50].  
2.3 Tyrosine Kinase  
Tyrosine kinase protein is an enzyme that catalyzes the process of transferring the 
gamma – phosphate group from an ATP molecule to tyrosine residues of numerous essential 
proteins, causing protein phosphorylation and signal transferring that aid in regulating cell 
cycle, cell proliferation, death and other several biochemical and physiological mechanisms 
[30].  
2.3.1 Tyrosine Kinase types 
The tyrosine kinases are divided into two types according to their structure: Receptor 
tyrosine kinases (RTK) and Non-receptor (NRTKs) or cellular tyrosine kinases. RTK is located 
on the cell surface and have an extracellular ligand binding domain, a transmembrane domain 
and an intracellular kinase domain [51]. RTKs would bind to ligands and cause 
phosphorylation of the tyrosine residues of the target proteins and then transmit signals through 
the signaling transduction pathways such as, RAS/RAF/MEK/ERK and PI3K/AKT/mTOR to 
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activate biochemical cascades within the cells [52] while the NRTKs are located either in the 
cytoplasm or in the nucleus that aid in the downstream signal transduction cascades. [53].  
2.3.2 Tyrosine Kinases in Cancer 
Disorders of tyrosine kinase proteins could lead to the development of serious diseases 
in the body, as mutations in these proteins are overrepresented by about four-fold compared 
with a random selection of genes and they are the most family of genes contribute to neoplastic 
disorders when they are mutated [54, 55]. It has been determined that tyrosine kinase proteins 
in healthy cells act as tumor suppressors or proto-oncogenes. However, aberrations in these 
proteins could cause irregular cell proliferation and eventually tumorigenesis, as more than 
50% of the proto-oncogenes and oncogenes expressing abnormal tyrosine kinase would be 
activated [56]. Moreover, tumor invasion, metastasis, angiogenesis and chemotherapy 
resistance are also seen due to the abnormal expression of tyrosine kinase protein [57].  
For example, mutations within the extracellular domain such as the EGFRv III mutation 
would cause a constitutive activity of the tyrosine kinase receptor that eventually leads to 
uncontrolled cell proliferation and this mutation have been seen in non-small cell lung 
carcinoma, glioblastomas and ovarian tumors [58, 59]. Also, cervical and human bladder 
carcinomas have been associated with somatic mutations in EGFR 2 and EGFR 3 [59]. The 
BCR-ABL chimeric gene responsible for CML development has higher tyrosine kinase activity 
by several folds than its normal equivalent that relates to the disease phenotype [60].  
2.4 Tyrosine Kinase Inhibitors 
Due to the involvement of tyrosine kinases in cancer, international research institutions 
and pharmaceutical groups have determined tyrosine kinase proteins as  targets for anti-cancer 
drug research, such as the development of tyrosine kinase inhibitors (TKI) [5]. TKIs are 
designed to block aberrant signals of the signaling transduction pathways that are associated to 
cell growth and proliferation and they are developed to either inhibit one or two tyrosine 
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kinases or even more tyrosine kinases in multiple signaling pathways. To do that, the TKIs 
would compete with the ATP for the ATP binding site of the tyrosine kinase and thus reducing 
the phosphorylation of the tyrosine kinase residues [61]. Consequently, this would assist in the 
anti-cancer mechanism of TKIs by causing tumor cell arrest in G1 phase, inhibition of tumor 
cells’ repair, induction of anti-angiogenesis and apoptosis. Also, these TKIs can be divided 
according to their main targets, VEGFR inhibitors, Bcr-Abl inhibitors, EGFR inhibitors and 
anaplastic lymphoma kinase (ALK) inhibitors [62, 63].   
2.4.1 Tyrosine Kinase Inhibitors as anti-cancer agents 
One example of a cancer that have been treated with TKIs is the Chronic Myeloid 
Leukemia (CML), as the outcomes of patients with CML have been transformed over the past 
fifteen years due to TKI therapy [64]. TKIs block the proliferation of the malignant cells by 
interfering with the BCR-ABL oncoprotein and adenosine triphosphate interaction [64]. 
Currently, for the first-line treatment of the CML chronic phase, the Food and Drug 
Administration (FDA) had approved three TKIs: Imatinib, Nilotinib and Dasatinib. Imatinib 
showed to be better than combination of interferon and cytarabine therapy, in terms of 
tolerability, cryptogenic and hematologic responses as well as in reducing the chances of 
developing the accelerated- or blast- phases of CML [6]. However, patients who are first-line 
TKI therapy intolerant or noncompliant, would have the second-line TKI therapy that include 
the second generation of TKIs, Nilotinib, Dasatinib and Bosutinib [64]. Although the third 
generation TKI, Ponatinib was the third-line treatment of choice, it has been seen to be 
associated with high risk of developing arterial and venous thromboembolism. Thus, only 
patients with the threonine-to-isoleucine mutation at position 315 (T315I), would have it as its 
more effective in those patients [65]. 
2.4.2 Toxicity of Tyrosine Kinase Inhibitors  
Toxicity profiles of each TKI drug should be determined before usage, as TKIs could 
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cause toxicity when they are taken alone or in combination. And their toxicity is either linked 
to their main target kinase, off-target consequence or due to a specific kinase inhibitor 
metabolite [66]. The most common side effects of TKIs are rash and diarrhea [67]. However, 
there are other side effects of the drugs that are explained by their action on normal tissues such 
as on the liver, heart and eyes [68, 69].  
The most concern of TKIs side effects is the cardiotoxicity in the cancer patients treated with 
those drugs [70]. For instance, several patients who have took Imatinib as an anti-cancer drug 
have expressed left ventricular dysfunction [71]. Also, compromised hemodynamics, 
pulmonary hypertension and cardiac failure have been observed as cardiotoxicity effects of the 
Dasatinib drug [72]. Ponatinib, a TKIs drug, have also showed adverse effects on the 
cardiovascular such as, heart failure, arterial occlusive events and hypertension [73].  
2.5 Zebrafish Model 
Nowadays, zebrafish are being used as a model in different studies such as, in 
behavioral, developmental, physiological, immunity and genetic studies [10]. Zebrafish or 
Danio rerio, in Latin, are small fish of the tropical freshwater that originates from the Ganges 
River [74] and they were first suggested as a research model by George Streisinger and his 
colleagues at Oregon University [75]. The advantages of using zebrafish as an animal model 
are, their genome is fully sequenced and easy to be manipulated, they have high fertility rate, 
rapid embryonic development (within 24 hours), short maturation period (3 months), the 
embryos’ organs and systems such as, the heart, the blood vessels and the intestine would be 
completed after 48 hours post-fertilization and the translucent embryos would aid in studying 
the embryogenesis developmental stages [10]. Moreover, there are several zebrafish transgenic 
lines and more than ten thousand mutants in the fish protein coding genes have been generated 
to help in studying human diseases, such as cardiovascular diseases, neural disorders and 
cancer [9]. In addition, the zebrafish genome has a high genetic similarity with the human 
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genome, as it has been estimated that at least 70% of the human genes have orthologue genes 
in the zebrafish genome [9]. Although, there are several strains of zebrafish worldwide, the 
only strains that are usually used in research laboratories are, AB, EKKwill, Casper, Tubingen, 
Nadia, wild-caught and Wild India Karyotype [10].  
2.5.1 Zebrafish Xenograft model 
Zebrafish are also being used as a model for the human cancers to test for the chemicals 
and drugs carcinogenicity and toxicity [76]. They spontaneously respond to carcinogens [77, 
78] and mutagens [79] and thus develop malignant tumors [79], with a tendency to increase in 
unstable genetic background or in loss of tumor suppressor functions such as, p53 [80]. 
Moreover, transgenesis of several types of common human tumors have been exhibited in 
zebrafish, for example, lung cancer, breast cancer, ovarian carcinoma, prostate cancer, 
leukemia and retinoblastoma [81]. This transplantation of human cancer cells into zebrafish, 
endorsed that the molecular mechanisms of mammalian tumorigenesis is similar in zebrafish 
[82]. Moreover, the transplantation of the cancer cells is possible due to the lack of an adaptive 













Chapter 3: Materials and Methods 
3.1 List of Materials 
• RPMI Medium 1640 (1X) (Gibco® Laboratories, Thermo Fisher Scientific, USA) 
• Human CML K-562 cell lines (ATCC® CCL-243™) 
• RecoveryTM Cell Culture Freezing Medium (Gibco® Laboratories, Thermo Fisher 
Scientific, USA) 
• FBS, Qualified, HI (Gibco® Laboratories, Thermo Fisher Scientific, USA) 
• DMSO (Dimethyl sulfoxide), anhydrous (Invitrogen™, Thermo Fisher Scientific, 
USA) 
• CellTrackerTM CM-Dil (Invitrogen™, Thermo Fisher Scientific, USA) 
• Penicillin-Streptomycin Antibiotic (Gibco® Laboratories, Thermo Fisher Scientific, 
USA) 
• Pluronic F-127 (Sigma Aldrich, Germany) 
• DPBS (1X) (Gibco® Laboratories, Thermo Fisher Scientific, USA) 
• Poly(lactide-co-glycolide)-fluorescein (Sigma Aldrich, Germany) 
• PLGA-PEG-PLGA (MW: 6000:10,000:6000 Da) (Akina, Inc., USA) 
• Ponatinib Free Base (LC Labs, USA) 
• PBS pH 7.4 (1X) (Gibco® Laboratories, Thermo Fisher Scientific, USA) 
• Tricaine  
• Tetrahydrofuran (VWR International, USA) 
• Milli Q Water purified by Milli Q system (Millipore, Molsheim, France) 
• Pronase  
• Egg Water 
• 1-phenyl 2-thiourea (PTU) 
• Trypan Blue Solution, 0.4% (Gibco® Laboratories, Thermo Fisher Scientific, USA) 
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• GlutaMAX (Gibco® Laboratories, Thermo Fisher Scientific, USA) 
3.2 List of Equipment 
• KOVA™ Glasstic™ Slide 10 with Grids (Fisher Scientific, USA) 
• Confocal Microscopy  
• Transmission electron microscope (TEM) 
• Olympus fluorescent microscopy 
• Analytical balance 
• Zebrafish imaging concave slide 
• Syringe Filter 0.45µm 
• Syringe Filter 0.2µm 
• Spectra-Por® Float-A-Lyzer® G2 membrane 
• Cryogenic Tubes 
• Vivaspin® 20 Ultrafiltration Unit (Sartorius Stedim Biotech, Germany) 
3.3 Methods 
3.3.1 Cell culture: 
Human CML K-562 cell line was obtained from ATCC and from the Interim 
Translational Research Institute (iTRI) at Hamad Medical Corporation (HMC). Cells have been 
cultured according to the optimum conditions described by the manufacturer. The cells have 
been cultured in RPMI 1640 (Gibco) supplemented with 10% FBS (Gibco), 10,000 U/mL 
Penicillin-Streptomycin (Gibco) and 100X GlutaMAX (Gibco) at 37°C in a humidified 5% 
CO2 incubator. The cells’ media were changed every alternative day to obtain the optimum 
cell count and maintain their viability at 90% following this equation: No. of viable cells / total 
No. of cells x 100. The cell counting was performed by taking out all the solution from the T75 
flasks into falcon tubes (15ml or 50ml), centrifuged at 1300 rpm for 5 min, the supernatant is 
discarded and then the pellets are re-suspended in 3-2 ml RPMI 1640 (Gibco) media. Then the 
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cell count was done manually using a KOVA™ Glasstic™ Slide 10 with Grids (Fisher 
Scientific) by taking 20μL of the cell suspension mixed with 20μL of the trypan blue stain and 
then 20μl of the mixture was loaded in the hemocytometer. Only the cells in the large 4 squares 
at the edges were counted under a light microscope. After that, the cell count in a ml was done 
following the equation: cell count x dilution factor (2) x the hemocytometer constant (104). 
After that to determine how much media were required to add into each T-75 flask for 




3.3.2 Fluorescent labeling of CML cells prior to xenotransplantation:  
Once the K-562 cells have reached confluency (1 x 106 cells/mL), they have been 
harvested by pelleting using a centrifuge at 1200 rpm for 5 minutes, the supernatant is then 
discarded then re-suspended in 3ml PBS mixed with 6μl 5 μg/ml CM-Dil fluorescent dye 
(Invitrogen). Then the dyed cells were incubated for 5 min at 37 °C followed by a 15 -20 min 
incubation at 4°C. After that, the cells were checked under the fluorescence microscope using 
fluorescent filters with excitation/emission spectra of 553/570 nm maxima. 
3.3.3 Tyrosine Kinase Inhibitor (TKI) Exposure Toxicity:  
The toxicity of the TKI drugs (i.e Ponatinib) was determined with the aid of Dr. Huseyin 
C. Yalcin lab member, Dr. Zain, a PhD graduate student. This was done by placing the fertilized 
embryos at 24 hpf in a 6-well cell culture plates with 20 embryos per well in 3 ml of the 
solution. Normal group were exposed to embryo media (EM). Negative control group was 
exposed to EM plus DMSO or PBS as vehicle, since drugs are dissolved in DMSO or PBS as 
needed to prepare the stock solutions. The experimental group was exposed to working 
solutions with different concentrations (0, 0.01, 0.1, 1, 10, 25, 50, and 100 mg/L) of the tested 
TKIs (Ponatinib). Doxorubicin and Imatinib have served as positive controls since these drugs 
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have known adverse cardiac toxicities. Then the embryos were placed in the incubator at 28°C 
and at the following days the survival rate was measured, and heart and tail videos were taken 
at 3dpf. 
3.3.4 Zebrafish husbandry: 
 Wild-type zebrafish embryos (AB strain) were used for this experimentation. All 
animal experiments were carried out according to national and international guidelines for the 
use of zebrafish in experimental settings [84] and in accordance with the animal protocol 
guidelines required by the Qatar University and policy on zebrafish research established by 
department of research in the Ministry of Public Health, Qatar (Ministry of Public Health, 
2017). This study has been approved by the Institutional Animal Care and Use Committee 
(IACUC); the approval document (QU-IACUC 019/2020) is found in the Appendix section 
(chapter 6). 
3.3.5 Xenografts injection procedure:  
The zebrafish embryos were exposed to Pronase at 24 hours post fertilization to remove 
the chorion. After that they were incubated till 2- or 3-days’ post fertilization (dpf) at 28°C. 
Dechorionated embryos were transferred to an injection slide and they were anesthetized with 
1% Tricane solution for destabilization. After that the fluorescently labeled K562 cells were 
injected to the yolk sac to allow the cells to enter into the blood circulation using a fashioned 
glass capillary needle. About 300 of the cancer cells’ K562 have been injected per embryo, 
using the Femtojet injector (Eppendorff) at the BRC zebrafish facility. The embryos were first 
anesthetized with 200mg/L Trican for 5 minutes and were aligned properly to have their body 
on one site to allow easier access to their yolk sacs. Then a capillary needle that have been 
prepared using borosilicate glass microcapillaries following the setting: air pressure, 500; heat, 
650; pull, 100; velocity, 200; time, 40, was used. A 10µl of the cells’ solution were then loaded 
into the needle and the needle is placed into a manipulator and adjust manipulator until holding 
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the needle with 45o angle with respect to embryo, the needle tip is break with tweezers and the 
cells’ solution was genteelly injected into the zebrafish embryos’ yolk sacs. After that the 
xenotransplanted embryos were transferred into new plates and fresh egg water and kept at 34 
°C till the end point at 7dpf. The zebrafish larvae were imaged under the fluorescence 
microscope using the ZEISS ZEN Microscope Software each day after injection to check the 
cancer cell spread and measure the tumor size. 
3.3.6 Preparation of the NPs:  
The PLGA- PEG- PLGA polymers were used to generate our NPs. 25mg of PLGA- 
PEG- PLGA polymers (Mw 6000:10000:6000) were measured by the analytical balance and 
added to a beaker along with 5mg of the fluorescently labeled PLGA with 5DTAF in order to 
have our particles to be fluorescent and then 10ml of THF were added with the PLGA polymers 
in one beaker with a magnetic stirrer and this was the “Organic solution”. At the same time but 
in another beaker along with a magnetic stirrer, 5mg Pluronic F127 was added in 20 ml milli 
Q water and this was the “water solution”. After that the organic solution was transferred into 
the water solution, very slowly, in a drop-by-drop approach to induce nanoprecipitation and 
embryonic nanoparticles formation. Finally, the dispersion was kept for overnight with a 
magnetic stirrer to evaporate the organic solvent. In the next day the NPs dispersion was filtered 
through 0.45 microm filter and the filtrate was placed in the ultrafiltration tube (Vivaspin® 20 
Ultrafiltration Unit) (Sartorius Stedim Biotech, Germany) to wash and concentrate the NPs. 
The tubes were placed in a centrifuge for 10 min 4500 RPM.    
3.3.7 TKI loaded NP preparation:  
The PLGA- PEG- PLGA polymers were used to generate drug loaded NPs. 25mg of 
PLGA- PEG- PLGA polymers (Mw 6000:10000:6000) were measured by the analytical 
balance and added to a beaker along with 5mg of the fluorescently labeled PLGA with 5DTAF 
in order to have our particles to be fluorescent, and for the TKIs loading, from Ponatinib drug 
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of 100mM stock concentration a 5mg (100ul), 10mg (200ul) or 15mg (300ul) was added and 
then 10ml of THF were also added with the PLGA polymers in one beaker with a magnetic 
stirrer and this was the “Organic solution”. At the same time but in another beaker along with 
a magnetic stirrer, 5mg Pluronic F127 was added in 20 ml milli Q water and this was the “water 
solution”. After that the organic solution was transferred into the water solution, very slowly, 
in a drop-by-drop approach to induce nanoprecipitation and embryonic nanoparticles 
formation. Finally, the dispersion was kept for overnight with a magnetic stirrer to evaporate 
the organic solvent. In the next day the NPs dispersion was filtered through 0.45 microm filter 
and the filtrate was placed in the ultrafiltration tube to wash and concentrate the NPs. The tubes 
were placed in a centrifuge for 10 min 4500 RPM. After three washing cycles for the free 
unencapsulated drug and the excess of the surface agent removal. NPs dispersions of a known 
concentration were prepared by redispersion of the concentrated NPs in a known volume of a 
milli Q water. 
3.3.8 NPs characterization 
3.3.8.1 Transmission Electron Microscope (TEM) 
TEM, which is a powerful instrument to characterize and image materials such as 
nanoparticles. TEM has been used to characterize the PLGA-PEG-PLGA nanoparticles. The 
procedure was carried by the Central Laboratories Unit (CLU) at Qatar University.  
3.3.8.2 Scanning Electron Microscope (SEM) 
 The particles surface morphology was assessed using NOVA NANOSEM 450 (N-
SEM) by the Central Laboratories Unit (CLU) at Qatar University. SEM uses a field emission 
gun as a source of electrons. The electron beam then travels through the column while being 
adjusted by different lenses till reaching the sample. The electrons interact with the sample 
producing secondary electrons and characteristic X-rays that can be detected by special 
detector to produce electron image and elemental spectra correspondingly. 
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3.3.8.3 Nanoparticles size 
Size of PLGA-PEG-PLGA nanoparticles have been measured by Nanosizer 2000 -
Malvern. The cuvette was filled by the NPs solution and inserted into the machine after 
selecting the corresponding refractive index of the NP.  
3.3.8.4 Zeta potential measurement   
The surface charges of the loaded and unloaded PLGA-PEG-PLGA nanoparticles were 
determined by the ZetaSIZER NANO -Malvern hosted at the Center for Advanced Materials 
(CAM) at Qatar University. The machine measures the Zeta potential by using electrophoretic 
light scattering. The PLGA-PEG-PLGA refractive index was obtained from the literature [85] 
and the NPs solution was then placed in a disposable folded capillary cell to be processed by 
the machine.   
3.3.8.5 Ponatinib Dissolution Rate 
To determine the dissolution rate of the loaded drug in the NPs, a dialysis membrane 
method have been done. This was performed using the Float-A-Lyzer G2 membrane, which 
trap the particles inside and allow the loaded drug to be released into the surrounding media. 
The NPs solution of 1 or 0.5ml have been loaded inside the membrane and the membrane was 
then placed inside a beaker filled with PBS buffer pH 7.4 with a magnetic stirrer at 37°C for 
24hr. After that, samples were taken for analysis from the same spot of the PBS buffer at regular 
intervals (1hr, 3hr, 5hr and 24hr).  
3.3.8.6 High-performance liquid chromatography (HPLC) 
HPLC is a technique to identify and quantify components in a mixture. Thus, HPLC 
analysis have been performed for the dissolution rate samples to identify and determine the 
presence of Ponatinib drug. This method has been done by the Central Laboratories Unit (CLU) 
at Qatar University. The eluents were, A) KH2PO4 0.0037 Molar (40%), PH 3.5 by H3PO4. 
Eluent: B) CH3CN (Acetonitrile) (60%). The flow rate was 1.2 ml/min, and the injection 
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amount was 5µl. The detector (PDA/UV) at 25nm wavelength and for the standard injected 
was a 5µl of the standard Ponatinib drug + 200µl of CH3CN (Acetonitrile). 
3.3.9 Unloaded NPs Toxicity 
The zebrafish embryos at 24 hours post fertilization (hpf) were exposed to 200µl 
Pronase solution for 10 min to remove the chorion. Dechorionized embryos were then 
evaluated under the stereo microscope and segregated into 6-wells plate equally (about 20 or 
24 embryos in each well). After that different concentrations of the unloaded NPs were 
prepared to determine the optimum concentration that will not cause any toxicity to the 
zebrafish embryos. The concentrations that have been prepared by diluting the proper amount 
of the NPs in PTU are: 1, 0.75, 0.5, 0.25, 0.1mg/ml. After that the PTU solution in the wells 
was removed and replaced with the diluted NPs solution. The embryos were then incubated at 
30°C and survival rate was then measured at 48 hpf and 72 hpf. 
3.3.10 Loaded NPs Toxicity     
The zebrafish embryos at 24 hours post fertilization (hpf) were exposed to 200µl 
Pronase solution for 10 min to remove the chorion. Dechorionized embryos were then 
evaluated under the stereo microscope and segregated into 6-wells plate equally (about 20 or 
24 embryos in each well). After that different concentrations of the three groups of loaded NPs 
with Ponatinib (5mg, 10mg and 15mg) were prepared to determine the optimum concentration 
that will not cause any toxicity to the zebrafish embryos. The concentrations that have been 
prepared from each of the three groups by diluting the proper amount of the NPs in PTU are: 
1, 0.75, 0.5, 0.25, 0.1, 0.05, 0.01, 0.005, 0.0025mg/ml. After that the PTU solution in the wells 
were removed and replaced it with the diluted NPs solution. The embryos were then incubated 
at 30°C and survival rate was measured at 48 hpf and 72 hpf. The surviving rate is calculated 
by dividing the number of the lived embryos over the total number of embryos multiplying by 
100.    
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3.3.11 Xenograft exposure of loaded PLGA-PEG-PLGA NPs assay: 
 Injected 2-dpf zebrafish embryos have been allowed to recover for half an hour 
after injecting with K562 cells before exposing them to 0.001mg/ml loaded PLGA-
PEG-PLGA NPs with 15mg and 10mg Ponatinib. The embryos have been separated in 
6-well plate. Two wells for each group (control, 15mg and 10mg) with 10 embryos in 
each. The 0.001mg/ml concentration of loaded PLGA-PEG-PLGA NPs were prepared 
by diluting it in egg water. For a total of 3ml, the required amount for one well; a 
1.440µl of the 15 and 10mg NPs was diluted in egg water. Then the embryos were 
incubated at 34°C and on 4-dpf embryos were imaged. 
3.3.12 Survival rate analysis 
At 48 hpf, the Dead embryos were removed from the 6-well cell culture plates to avoid 
influencing the surviving embryos during the toxicity experiments. The numbers of the dead, 
surviving and abnormal embryos of each NPs concentration groups were recorded until 3 dpf 
or 72 hpf. The surviving rate is calculated by dividing the number of the lived embryos over 
the total number of embryos multiplying by 100.   
3.3.13 Cardiovascular structure/function analysis 
To check for the cardiovascular toxicity of the unloaded and loaded NPs, the analysis 
was carried out at 3-dpf for the embryos in all the treated groups to see the influence of 
interference on cardiac function, structure and on the blood flow. The treated embryos were 
first fixed on a concave slide for imaging using 3% methyl cellulose. Under the Hamamatsu 
Orca high-speed camera and Zeiss Lumar V12 stereo microscope, images and high-speed time-
lapse movies were recorded at about 100 fps for the heart and tail of each embryo through the 
HCImage software. Then to assess for the heart failure due to the toxicity of the nanoparticles, 
analysis of the gross cardiac structure for the presence of cardiac edema and major structural 
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defects such as looping defects was performed. Also, tail videos have been analyzed for the 
Red Blood Cells (RBCs) movement within the blood flow using the MicroZebraLab. Tracking 
the RBCs aids in measuring the blood velocity by following an in-house algorithm from 
Viewpoint for tracking RBCs. This algorithm has also used to measures heart rate in beats per 
minute that to calculate other cardiac function parameters such as cardiac output. Through 
extracting frames at end-diastole and end-systole points for calculating myocardial thickness 
and ventricular volumes. Increased myocardial thickness was associated with the presence of 
hypertrophy. Then the ventricular volumes at end-diastole and end-systole were determined to 
calculate several cardiac function parameters as outlined below. Assuming a prolate spheroidal 
shape, the following formula was used for ventricular volumes: 
𝑉𝑜𝑙𝑢𝑚𝑒 = 	
1
6	× 𝜋 × 𝐷! × 𝐷"
# 
Here, DL and DS are long-axis and short-axis diameters, respectively. Stroke volume (SV) is 
the blood volume pumped from the ventricle for each beat and is simply calculated from 
ventricle volumes at end-diastole and end-systole: 
𝑆𝑉 = (𝐸𝐷𝑉 − 𝐸𝑆𝑉) 
Here EDV and ESV are end-diastole and end-systole volumes. Ejection fraction (EF) is defined 
as the fraction of blood ejected from the ventricle with each heartbeat: 
𝐸𝐹	(%) = 	
(𝐸𝐷𝑉 − 𝐸𝑆𝑉)
𝐸𝐷𝑉 × 100 =
𝑆𝑉
𝐸𝐷𝑉 × 100 
Cardiac output (CO) is the volume of blood being pumped by the heart. CO was calculated 
from SV and heart rate (HR) as follows: 
CO (nanoliter/min) = SV (nanoliter/beat) × HR (beats/min) 
FS is another measure of ventricular contractility. It was calculated from ventricle diameters at 







3.3.14 Gene Expression via RT-PCR 
  The total RNA was isolated from 3dpf embryos treated with the TKIs (Ponatinib and 
Imatinib) and the control embryos by using the IBI DNA/RNA/Protein Extraction Kit (IBI 
Scientific -r IB47702) and following the manufacture instructions. Then the first-strand cDNA 
synthesis was done by following the manufacture instructions of the SuperScript™ IV VILO™ 
Master Mix kit (Thermo Fisher Scientific 11756050). After that, for the quantitative analysis 
of specific mRNA expression, Taqman real-time reverse transcriptase (Applied Biosystems®) 
and specific primers and probs that was designed and constructed (Applied Biosystems®) 
against the genes of interest; atrial natriuretic peptide (ANP) and brain natriuretic peptide 
(BNP) Table (1) have been used. The signal was read using the Real-Time PCR ABI 7500 
System. While the relative quantity was calculated based on the 2-ΔCт method [86] and the 
fold change was calculated in reference to the control group. 
 
Table 1: List of primers for RT-qPCR 
 
 
3.3.15 Statistical analysis 
Statistical analysis was performed using GraphPad Prism version 9 software. Data were 
analyzed using one way-ANOVA with Dunnet’s multiple comparison test. A p-value of less 
than 0.05 was considered statistically significant. One asterisk (*) indicates p<0.05, two 
asterisk (**) indicates p<0.01, three asterisk (***) p<0.001 and four asterisk (****) indicates 
p<0.0001. 
 
Cataloge no. Gene Name RefSeq Species
4331348 ANP – nppa zebrafish NM_198800 Zebrafish
4331348 BNP – nppa zebrafish NM_001327776 Zebrafish
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Chapter 4: Results  
4.1 Fluorescent K562 
Olympus fluorescent microscope was used to image the fluorescent K562 CML cells 
stained with CM-Dil fluorescent dye. The mCherry fluorescent filter with excitation/emission 
spectra of 587/610 has been chosen to examine the fluorescent K562 CML cells as the CM-Dil 
fluorescent dye has an excitation/emission of 553/570 nm maxima. Figure (1) represent an 
image of the fluorescent K562 cells at 60X magnification. As seen from the figure, most of the 












Figure 1: Fluorescently labelled K562. 
Representative fluorescence images for K562 cells stained with CM-Dil dye (Red). 
Fluorescently labeled K562 cells at magnification 60X; Scale bar, 0.03mm.  
 
 
4.2 PLGA-PEG-PLGA NPs characterization 
4.2.1 PLGA-PEG-PLGA NPs morphology 
 TEM and SEM were used to characterize the shape of the PLGA-PEG-PLGA NPs. 




the NPs with a round shape. Figure (2, B) represents the shape of PLGA-PEG-PLGA NPs 










Figure 2: TEM and SEM micrographs of PLGA-PEG-PLGA NPs. 
(A) TEM image of PLGA-PEG-PLGA Np on scale bar, 50 nm. (B) SEM image of PLGA-
PEG-PLGA Nps on scale bar, 1µm. 
 
 
4.2.2 PLGA-PEG-PLGA NPs size 
 The size of loaded PLGA-PEG-PLGA NPs with 5mg, 10mg and 15mg Ponatinib have 
been measured using the Nanosizer 2000-Malvern machine. The range of the NPs was around 
80 to 100nm. The exact sizes of each NP group were, 74.55+/- 28.74 (d.nm)±SD for the PLGA-
PEG-PLGA NPs loaded with 5mg Ponatinib Figure (3, A), 125+/- 26.91 (d.nm)±SD for the 
PLGA-PEG-PLGA NPs loaded with 10mg Ponatinib Figure (3, B) and 116.9+/- 42.92 
(d.nm)±SD for PLGA-PEG-PLGA NPs loaded with 15mg Ponatinib Figure (3, C). 
While the size of the unloaded PLGA-PEG-PLGA NPs was showed to be 84.33+/-
13.83 (d.nm)±SD Figure (4). Indicating that PLGA-PEG-PLGA NPs have a size range 
approximately from 80 to 100nm and the loading of Ponatinib drug had showed to have a slight 























Figure 3: Ponatinib loaded PLGA-PEG-PLGA NPs intensity based particles size 
distribution. 
Representative graphs of Nanosizer 2000-Malvern for loaded PLGA-PEG-PLGA NPs size (A) 
The size of PLGA-PEG-PLGA NPs loaded with 5mg Ponatinib is 74.55+/- 28.74 (d.nm)±SD 
(B) The size of PLGA-PEG-PLGA NPs loaded with 10mg Ponatinib is 125+/- 26.91 

















Figure 4 :Unloaded PLGA-PEG-PLGA NPs intensity based particles size distribution. 
Representative graph of Nanosizer 2000-Malvern for unloaded PLGA-PEG-PLGA NPs size. 
Size of unloaded PLGA-PEG-PLGA NPs is 84.33+/-13.83 (d.nm)±SD. 
 
 
4.2.3 PLGA-PEG-PLGA NPs surface charge 
 The surface charge of the PLGA-PEG-PLGA NPs has been assessed to know more 
about the material properties, thus its interaction with the biological system can be predicted.   
For that, zeta potential for the loaded PLGA-PEG-PLGA NPs has been measured by the 
Nanosizer 2000-Malvern machine and the surface charge of the particles revealed to be 
positively charged as 12,3+/-5.5; 15,2+/-3.4 and 16,7+/-2.5 (mV)±SD for 15, 10 and 5mg 
PLGA-PEG-PLGA respectively Table (2).  
 While the zeta potential for the unloaded PLGA-PEG-PLGA NPs have been measured 
by the ZetaSIZER NANO-Malvern hosted at the Center for Advanced Materials (CAM) at 
Qatar University. The particles surface charge revealed to be negatively charged with an 
average of -2.66+/-0.185 (mV)±SD Table (3). The surface charge of the Ponatinib drug have 
also been measured which showed that the drug has a positive surface charge in an average of 
30.86+/- 2.744(mV)±SD zeta potential Table (4), which seems to be the reason for changing 
of the surface charge of the particles when loaded with the drug.  
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Sample Name Zeta Potential (mV)
Unloaded Nano particles 1 -2.48
Unloaded Nano particles 2 -2.85
Unloaded Nano particles 3 -2.65
Mean -2.66
STD 0.185








Sample name Zeta Potential (mV) +/- STD
1 PLGA-PEG-PLGA NPs loaded with 5mg Ponatinib 16,7+/-2.5
2 PLGA-PEG-PLGA NPs loaded with 10mg Ponatinib 15,2+/-3.4 
3 PLGA-PEG-PLGA NPs loaded with 15mg Ponatinib 12,3+/-5.5
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4.2.4 Ponatinib Dissolution Rate from PLGA-PEG-PLGA NPs 
 To determine the dissolution rate of Ponatinib drug, or the % of the released drug from 
the particles into the solution as a free drug, HPLC analysis of the dissolution samples from 
dissolution test have been performed. Figure (5, A) represent the standard graph of Ponatinib 
drug where it showed a peak at 1.678 retention time (RT).   
Figure (5, B) of loaded PLGA-PEG-PLGA NPs with 5mg sample collected at 1 hour 
showed a clear peak at 1.699 RT indicating that Ponatinib have been released from the particles 
at the first hour. Although Figure (5, C), which represent loaded PLGA-PEG-PLGA NPs with 
5mg sample collected at 3 hours, has also showed a tiny peak at 1.699 RT, it was not 
significantly considered a clear release of the drug. While Figures (5, D) and (5, E) of loaded 
PLGA-PEG-PLGA NPs with 5mg sample collected at 5 hour and 24 hours respectively, did 
not showed any release of the drug in the buffer solution. 
In the other hand, loaded PLGA-PEG-PLGA NPs with 10mg and 15mg samples did 
not show any release peak of the drug from the particles into the buffer at any time interval of 
1hr, 3hr, 5hr 24hr and 48hr Figure (5, F, G, H, I, J, K, L, M, N & O). Although there was a 
release of Ponatinib at the first hour from the 5mg PLGA-PEG-PLGA NPs, this rapid release 
is undesirable as this won’t allow a longer circulation of the loaded NPs in vivo, but 10 and 
15mg Ponatinib loaded PLGA-PEG-PLGA NPs did not show that, indicating the release of the 
































Figure 5: Ponatinib Dissolution Rate from PLGA-PEG-PLGA NPs. 
Representative graphs of HPLC for Ponatinib Dissolution Rate from PLGA-PEG-PLGA NPs 
(A) Standard graph of Ponatinib drug peak at 1.678 RT. (B) PLGA-PEG-PLGA NPs loaded 
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with 5mg Ponatinib at 1hr. (C) PLGA-PEG-PLGA NPs loaded with 5mg Ponatinib at 3hr. (D) 
PLGA-PEG-PLGA NPs loaded with 5mg Ponatinib at 5hr. (E) PLGA-PEG-PLGA NPs loaded 
with 5mg Ponatinib at 24hr. (F) PLGA-PEG-PLGA NPs loaded with 10mg Ponatinib at 1hr. 
(G) PLGA-PEG-PLGA NPs loaded with 10mg Ponatinib at 3hr. (H) PLGA-PEG-PLGA NPs 
loaded with 10mg Ponatinib at 5hr. (I) PLGA-PEG-PLGA NPs loaded with 10mg Ponatinib at 
24hr. (J) PLGA-PEG-PLGA NPs loaded with 15mg Ponatinib at 1hr. (K) PLGA-PEG-PLGA 
NPs loaded with 15mg Ponatinib at 3hr. (L) PLGA-PEG-PLGA NPs loaded with 15mg 
Ponatinib at 5hr. (M) PLGA-PEG-PLGA NPs loaded with 15mg Ponatinib at 24hr. (N) PLGA-
PEG-PLGA NPs loaded with 10mg Ponatinib at 48hr. (O) PLGA-PEG-PLGA NPs loaded with 
15mg Ponatinib at 48hr. 
 
 
4.3 Ponatinib Toxicity 
4.3.1 Survival Rate 
 Before, we assessed loaded nanoparticles, we first wanted to see how cardiotoxic 
Ponatinib is on zebrafish embryos. The survival rate of the zebrafish embryos at 24hr, 48hr and 
72hr -post fertilizing (hpf) was calculated for the control, Ponatinib treated groups as well as 
for Imatinib as a first generation TKI. Figure (6) indicates that there is a significant decrease 
in the survival rate of 10μM and 5μM Ponatinib groups comparing to the normal and negative 
control groups (Control and 0.1%DMSO). Ponatinib was similarly cardiotoxic as Imatinib and 
the Ponatinib treated group with the lowest concentration (2.5μM) did not show any significant 






Figure 6: Ponatinib and Imatinib Survival Rate. 
Survival rate of embryos exposed to different concentrations of Ponatinib and Imatinib 
compared to the PC (1μM AA) and NC, at different timepoint 24,48,72 hpf. n= 20, (*) = p < 




4.3.2 Cardiovascular structure assessment  
The cardiac structure was assessed by observing the morphological structure of the heart using 
the Hamamatsu Orca high-speed camera and Zeiss Lumar V12 stereo microscope. The 
embryos were photographed, and the phenotype of the treated group embryos were compared 
to the control and normal embryos Figure (7, A). For the treated group by the lowest 
concentration (2.5 and 5µM) of Imatinib Figure (7, B & C), the embryos heart showed to be 
normal but for the highest concentration (10µM) Figure (7, D) abnormal heart and size was 
shown. For Ponatinib (2.5 and 5µM) Figure (7, E & F) there was several abnormalities 
observed. This includes pericardial edema, lordosis or the combination of both. Edema has 
showed to be the most common among the embryos treated with Ponatinib and edema has 




























Figure 7: Embryo phenotypes following treatment with different concentrations of 
Imitinab and Ponitinab. 
(A)  DMSO (0.1%) treated embryos with normal heart size and shape. (B) Imatinib (2.5µM) 
treated embryos with normal heart size and shape, (C) Imatinib (5µM) treated embryos of 
normal heart size and shape.  (D) Imatinib (10µM) treated embryos showed abnormal heart 
size and shape.  (E) Ponatinib (2.5µM) and (F) Ponatinib (5µM) showed elongated tub-like 
structure heart and pericardial edema when compared to control. 
 
 
4.3.3 Cardiac function assessment 
 The cardiac function was assessed by analyzing the dorsal aorta blood flow of the 
2.5μM Ponatinib and Imatinib exposed groups. The aorta blood flow velocity of both TKIs 
significantly decreased compared to the normal and negative controls Figure (8, A). The aorta 
diameter has also been reduced compared to the control groups Figure (8, B). However, the 
















Figure 8: Ponatinib and Imatinib dorsal aorta blood flows analysis. 
(A) Aorta blood flow velocity of Ponatinib and Imatinib (2.5μM) exposed embryos. (B) Aorta 
Diameter of Ponatinib and Imatinib (2.5μM) exposed embryos. (C) Aorta Pulse of Ponatinib 
and Imatinib (2.5μM) exposed embryos. (*) = p < 0.05; (***) = p < 0.001, (****) = p <0.0001. 
 
 
4.3.4 Cardiac markers gene expression 
 Ponatinib and Imatinib (2.5μM) have showed to be significantly increased the gene 
expression of atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) compared 
to the negative control (DMSO (0.1%)) indicating severe cardiotoxicity Figure (9). Here AA 
is a well-known agent for heart failure, was used as a positive control. Ponatinib and Imatinib 
had similar cardiotoxicities. These findings clearly demonstrated that Ponatinib is associated 














Figure 9: Gene expression fold changes in ANP and BNP cardiac markers. 
The relative quantity was calculated based on the 2-ΔCт method, and the fold change was 




4.4 Unloaded PLGA-PEG-PLGA NPs Toxicity 
4.4.1 Survival rate 
The survival rate of the zebrafish embryos at 72hr -post fertilizing (hpf) was calculated 
for the negative control (NC) and treated groups of unloaded PLGA-PEG-PLGA NPs. Figure 
(10) indicates that there is a significant decrease in the survival rate of 1.0 mg/ml group 
compared to the negative control group. While the experiment groups with the lowest 
concentration (0.75, 0.5, 0.25, 0.1 and 0.05 mg/ml) of unloaded PLGA-PEG-PLGA NPs did 


























Figure 10: Unloaded PLGA-PEG-PLGA NPs Survival Rate. 
Survival rate of embryos exposed to different concentrations of unloaded PLGA-PEG-PLGA 
NPs compared to the NC, at 72 hpf. (*) = p < 0.05. 
 
 
4.4.2 Cardiac function assessment 
The cardiac function was assessed by analyzing the heartbeat, the dorsal aorta (DA) 
and posterior cardinal vein (PCV) vessel diameter and blood flow velocity. The heartbeat of 
0.75 mg/ml exposed group was significantly reduced compared to the negative control Figure 
(11, A).  
The dorsal aorta (DA) vessel diameter has been shown to be enlarged in groups (1.0, 
0.5 and 0.25 mg/ml) and the blood velocity was increased significantly in the 0.25 mg/ml group 
compared to the negative control Figure (11, B & C).  
In the posterior cardinal vein (PCV) the vessel diameter has been shown to be enlarged 
in groups (0.5, 0.25, 0.1 mg/ml) and the blood velocity was also seen to be increased 
significantly in the 0.25 mg/ml group Figure (11, D & E). Based on these results, only high 
concentration of unloaded NPS seem to be toxic to the animals. 
 
 












































Figure 11: Cardiac function assessment of unloaded PLGA-PEG-PLGA. 
(A) Heartbeat of embryos exposed to different concentrations of unloaded PLGA-PEG-PLGA 
NPs. (B) DA vessel diameter of embryos exposed to different concentrations of unloaded 
PLGA-PEG-PLGA NPs. (C) DA blood flow velocity of embryos exposed to different 
concentrations of unloaded PLGA-PEG-PLGA NPs. (D) PCV vessel diameter of embryos 
exposed to different concentrations of unloaded PLGA-PEG-PLGA NPs. (E) PCV blood flow 













































































































velocity of embryos exposed to different concentrations of unloaded PLGA-PEG-PLGA NPs. 
(*) = p < 0.05; (***) = p < 0.001, (****) = p <0.0001. 
 
 
4.5 Loaded PLGA-PEG-PLGA NPs Toxicity 
4.5.1 Survival rate 
The survival rate of the zebrafish embryos at 72hr -post fertilizing (hpf) was calculated 
for the negative control and treated groups of loaded PLGA-PEG-PLGA NPs with 5, 10 and 
15mg Ponatinib. Figure (12, A) of the of loaded PLGA-PEG-PLGA NPs with 5mg Ponatinib 
indicates that higher concentrations of the loaded PLGA-PEG-PLGA NPs (1 and 0.75 mg/ml) 
have the lowest survival rate compared to the other groups. Figure (12, B) of the of loaded 
PLGA-PEG-PLGA NPs with 10mg Ponatinib showed that 1 and 0.5 mg/ml groups have the 
lowest survival rate. And Figure (12, C) of the of loaded PLGA-PEG-PLGA NPs with 15mg 
Ponatinib also showed that 1 and 0.75 mg/ml exposed groups have the lowest survival rate 
compared to the other groups.  
Based on these results, only high concentration of loaded NPs seems to be toxic to the 
animals and the concentration of 0.001 mg/ml in 10 and 15mg Ponatinib loaded NPs showed 
to have similar survival rate to the negative control providing that this concentration is the most 
optimum than the others. While the concentration of 0.001 in 5mg did not show similar results 























Figure 12: Loaded PLGA-PEG-PLGA NPs Survival Rate. 
(A) Survival rate of embryos exposed to different concentrations of 5mg Ponatinib loaded 
PLGA-PEG-PLGA NPs compared to the NC, at 72 hpf. (B) Survival rate of embryos exposed 
to different concentrations of 10mg Ponatinib loaded PLGA-PEG-PLGA NPs compared to the 
NC, at 72 hpf. (C) Survival rate of embryos exposed to different concentrations of 15mg 
Ponatinib loaded PLGA-PEG-PLGA NPs compared to the NC, at 72 hpf. (*) = p < 0.05. 
 
 
4.5.2 Cardiac function assessment  
The cardiac function was assessed by analyzing the heartbeat, the dorsal aorta (DA) 
and posterior cardinal vein (PCV) vessel diameter and blood flow velocity. The heartbeat of 
groups 5mg; 0.005 and 0.0025mg/ml, 10mg; 0.005, 0.0025 and 0.001mg/ml and 15mg; 0.0025 
and 0.001 mg/ml were significantly reduced compared to the negative control Figure (13, A).  
The dorsal aorta (DA) vessel diameter has been shown to be enlarged in all the testable 




























































































0.001mg/ml). And the blood velocity was significantly reduced in 15mg (0.005mg/ml) and 
high but not significantly in 15mg (0.0025mg/ml) Figure (13, B & C).  
In the posterior cardinal vein (PCV) the vessel diameter has been shown to be 
significantly enlarged in 5mg (0.0025mg/ml), 10mg (0.005, 0.0025, 0.001mg/ml) and 15mg 
(0.005, 0.0025, 0.001 mg/ml) the blood velocity was significantly reduced in 15mg 
(0.005mg/ml) Figure (13, D & E). 
According to these results 0.001 mg/ml from both 10mg and 15 mg concentrations seem 
to be non-toxic, and these would be used further in the xenograft experiments since targeting 






























































Figure 13: Cardiac function assessment of loaded PLGA-PEG-PLGA NPs. 
(A) Heartbeat of embryos exposed to different concentrations of loaded PLGA-PEG-PLGA 
NPs with 5, 10 or 15mg Ponatinib. (B) DA blood flow velocity of embryos exposed to different 
concentrations of loaded PLGA-PEG-PLGA NPs with 5, 10 or 15mg Ponatinib. (C) DA vessel 
diameter of embryos exposed to different concentrations of loaded PLGA-PEG-PLGA NPs 




















































































































DA Blood Flow Velocity































































PCV Blood Flow Velocity















































































































































concentrations of loaded PLGA-PEG-PLGA NPs with 5, 10 or 15mg Ponatinib. (E) PCV 
vessel diameter of embryos exposed to different concentrations of loaded PLGA-PEG-PLGA 
NPs with 5, 10 or 15mg Ponatinib. (*) = p < 0.05; (***) = p < 0.001, (****) = p <0.0001. 
 
4.6 Zebrafish Xenograft Model 
 K562 CML cell line was successfully transplanted into the 72-hpf zebrafish embryos. 
Figure (14) represents a xenografted embryo from one day post injection to three days post 
injection (dpi) compared to a negative control embryo to differentiate between the 
autofluorescence of the embryos. The fluorescently labeled cancer cells with CM-Dil red 
fluorescent dye have been seen to increase in mass and spread into further sites of the embryo 
over time as indicated by the white arrows. The yolk sac area (white X) which was the injection 
site of the cells, showed the most tumor mass. Also, cancer cells showed to circulate through 




































Figure 14: Zebrafish Xenograft model injected at 3 dpf. 
Zebrafish screening at 4 dpf to 6 dpf using fluorescent microscopy and investigation of 
fluorecent K562 cells proliferation (White solid arrows) through out the animal body (Y: eyes, 
X: yolk sac, Z: tail) using mCherry fluorescence filter. 
Negative Control (NC)
Xenograft Embryo at 4 dpf or 
1dpi
Xenograft Embryo at 5 dpf or 
2dpi










K562 CML cell line was also successfully transplanted when injected into the 48-hpf 
zebrafish embryos. Figure (15) represent a xenografted embryo from one day post injection to 
five days post injection (dpi) compared to a negative control embryo to differentiate between 
the autofluorescence of the embryos. The fluorescently labeled cancer cells have been seen to 
increase in mass and circulate into further sites of the embryo over time as indicated by the 
white arrows.  The yolk sac area (white X) which was the injection site of the cells also showed 
the most tumor mass. And the cells have also showed to circulate through the blood as seen in 
























Figure 15: Zebrafish Xenograft model injected at 2 -dpf. 
Zebrafish screening at 3 dpf to 7 dpf using fluorescent microscopy and investigation of 
fluorecent K562 cells proliferation (White solid arrows) through out the animal body (Y: eyes, 
X: yolk sac, Z: tail) using mCherry fluorescence filter.  
 
 
4.7 Xenograft model exposed to loaded PLGA-PEG-PLGA NPs  
Loaded PLGA-PEG-PLGA NPs with 10mg Ponatinib of 0.001mg/ml concentration 
Negative Control (NC)
Xenograft Embryo at 3 dpf or 
1dpi
Xenograft Embryo at 4 dpf or 
2dpi
Xenograft Embryo at 5 dpf or 
3dpi
Xenograft Embryo at 6 dpf or 
4dpi














have been used to be exposed to the 2dpf xenograft embryos at the same day of the cancer cells 
injection. Figure (16) represent a xenografted embryo from two-day post injection and NPs 
exposure to five days post injection (dpi) and NPs exposure compared to a negative control 
embryo. The fluorescently labeled cancer cells have been seen to increase in mass and circulate 
into further sites of the embryo over time as indicated by the white arrows.  The yolk sac area 
(white X) which was the injection site of the cells also showed the most tumor mass. And the 
cells have also showed to circulate through the blood as seen in the embryo eyes (white Y) and 
tail (white Z), indicating that the loaded NPs are taking long time to release Ponatinib, as shown 







































Figure 16: Xenograft model exposed to loaded PLGA-PEG-PLGA NPs with 10mg 
Ponatinib. 
Zebrafish screening at 4 dpf to 7 dpf using fluorescent microscopy and investigation of 
fluorecent K562 cells proliferation (White solid arrows) through out the animal body (Y: eyes, 
X: yolk sac, Z: tail) using mCherry fluorescence filter after exposing zebrafish embryos to 
0.001mg/ml of loaded PLGA-PEG-PLGA NPs with 10mg Ponatinib. 
Negative Control (NC)
Xenograft Embryo exposed to 
10mg Ponatinib loaded PLGA-
PEG-PLGA NPs imaged at 4 dpf 
or 2dpi
Xenograft Embryo exposed to 
10mg Ponatinib loaded PLGA-
PEG-PLGA NPs imaged at 5 dpf 
or 3dpi
Xenograft Embryo exposed to 
10mg Ponatinib loaded PLGA-
PEG-PLGA NPs imaged at 6 dpf 
or 4dpi
Xenograft Embryo exposed to 
10mg Ponatinib loaded PLGA-












Also, loaded PLGA-PEG-PLGA NPs with 15mg Ponatinib of 0.001mg/ml concentration 
have been used to be exposed to the 2dpf xenograft embryos at the same day of the cancer cells 
injection. Figure (17) represent a xenografted embryo from two-day post injection and NPs 
exposure to five days post injection (dpi) and NPs exposure compared to a negative control 
embryo. The fluorescently labeled cancer cells have been seen to increase in mass and circulate 
into further sites of the embryo over time as indicated by the white arrows.  The yolk sac area 
(white X) which was the injection site of the cells also showed the most tumor mass. And the cells 
have also showed to circulate through the blood as seen in the embryo eyes (white Y) and tail 
(white Z),indicating that the loaded NPs are taking long time to release Ponatinib, as shown that 


























Figure 17: Xenograft model exposed to loaded PLGA-PEG-PLGA NPs with 15mg Ponatinib. 
Zebrafish screening at 4 dpf to 7 dpf using fluorescent microscopy and investigation of fluorecent 
K562 cells proliferation (White solid arrows) through out the animal body (Y: eyes, X: yolk sac, 
Z: tail) using mCherry fluorescence filter after exposing zebrafish embryos to 0.001mg/ml of 





Xenograft Embryo treated with 
15mg Ponatinib loaded PLGA-
PEG-PLGA NPs imaged at 4 dpf 
or 2dpi
Xenograft Embryo treated with 
15mg Ponatinib loaded PLGA-
PEG-PLGA NPs imaged at 5 dpf 
or 3dpi
Xenograft Embryo treated with 
15mg Ponatinib loaded PLGA-
PEG-PLGA NPs imaged at 6 dpf 
or 4dpi
Xenograft Embryo exposed to 
15mg Ponatinib loaded PLGA-











4.8 Loaded PLGA-PEG-PLGA NPs uptake  
 Figure (18) showed the successful uptake of the fluorescence labeled loaded PLGA-PEG-
PLGA NPs with 10 or 15mg Ponatinib after 2dpi or 2 days after treatment comparing to the 
negative control. The loaded PLGA-PEG-PLGA NPs were stained by 5DTAF a green fluorescence 
colored dye, that have been seen under the GFP filter. White arrows are showing the fluorescence 













Figure 18: Loaded PLGA-PEG-PLGA NPs uptake. 
Zebrafish screening at 4 dpf using fluorescent microscopy and investigation of fluorecent PLGA-
PEG-PLGA NPs distribution (White solid arrows) through out the animal body (Y: eyes, X: yolk 










10mg Ponatinib loaded PLGA-
PEG-PLGA NPs distribution in 
Xenograft Embryo imaged at 4 
dpf or 2dpi
15mg Ponatinib loaded PLGA-
PEG-PLGA NPs distribution in 








Chapter 5: Discussion  
As cancer is one of the main causes of death worldwide, many research studies are currently 
focusing on finding new and efficient therapies to reduce side effects associated with conventional 
therapies of cancer [87]. Nanomedicine is one of the new approaches to overcome the cancer 
conventional therapies related issues such as, the low bioavailability and low specificity of the 
cancer drugs or contrast agents [88]. Thus, encapsulating the anti-cancer drugs or the active agents 
in nanoparticles would increase their biocompatibility, solubility, stability in body fluids and their 
retention time in tumor vasculature which would enhance the efficacy of the treatment [89-91].  
Moreover, nanomedicine could also aid in cardio-oncology which is an inter-disciplinary 
field of studying, detection and treating cardiovascular adverse effects due to cancer therapies [92]. 
Although, TKIs are effective and preferred choice of therapy in several kind of cancers, such as 
CML, their toxicity remains a major concern particularly the cardiotoxicity in the cancer patients 
[70]. Therefore, in this study the TKI, Ponatinib has been loaded into the PLGA-PEG-PLGA NPs 
in order to enhance the anti-cancer efficacy and reduce cardiotoxicity related to TKIs.  
First of all, to determine the cardiotoxicity of the anti-cancer TKI drug i.e., Ponatinib, the 
zebrafish model has been used in this study due to the transparency of the zebrafish embryos that 
allows a non-invasive examination of the organ development and toxic end points of the tested 
drugs [93]. The cardiotoxicity was determined by the morphological structure and by measuring 
the survival rate, cardiac outputs and atrial natriuretic peptide (ANP) and B-type natriuretic peptide 
(BNP) mRNA expression. Ponatinib has showed the most cardiotoxicity compared to the other 
TKI i.e., Imatinib with abnormal heart size and shape and the presence of pericardial edema. The 
aorta diameter, blood flow velocity and aorta cardiac output were significantly reduced. Also, the 
atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) showed a significant high 
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fold change compared to the normal control, and these natriuretic peptides play many important 
roles such as regulating blood pressure and blood volume, in regulating the permeability of the 
systemic vasculature, cellular proliferation and growth [94]. Also, BNP and ANP are the most 
common used diagnosed markers for heart failure [95].  
This cardiotoxicity of Ponatinib has also seen by other previous studies who tested 
Ponatinib on the zebrafish model. For instance, Singh et. al. (2019), has used the BNP reporter line 
of the transgenic zebrafish and they have reported that Ponatinib showed the most cardiotoxicity 
compared to other CML TKIs by inhibiting cardiac pro-survival signaling pathways AKT and the 
extracellular signal regulated kinase (ERK) as well as to induce cardiomyocyte apoptosis [96]. 
While Zhu et. al. (2020), has used Ponatinib to induce ischemic stroke model of zebrafish 
indicating that the pathophysiology Ponatinib in inducing ischemic stroke is similar to that of 
ischemic stroke in humans [97].  
Secondly, the smart nanoparticle PLGA-PEG-PLGA NPs has been synthesized through 
mixing the organic solution (PLGA- PEG- PLGA polymers, fluorescently labeled PLGA and THF) 
with the water solution (Pluronic F127 and milli Q water). The PLGA-PEG-PLGA NPs 
characteristics (size, shape and surface charge) have been studied. The size of the empty PLGA-
PEG-PLGA NPs showed to be 84.33nm. However, Sulaiman et. al. (2019) has shown that the 
PLGA- PEG- PLGA NPs size is in the range of 206 to 402 nm, demonstrating that the experimental 
design for preparing PLGA-PEG-PLGA polymers has effects on the polymers size [98]. SEM has 
showed the NPs to be spherical in 3- dimensions with smooth surface. This is because SEM is used 
to examine material surfaces and it’s based on scattered electrons [99]. While, TEM showed the 
NPs to be round of clear internal elements, TEM was used to show the NPs in a higher 
magnification as it’s based on transmitted electrons and it has a higher electron energies than SEM 
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that allows them to penetrate through the particles to define any internal elements in the particles 
[99]. Moreover, the surface charge of the empty PLGA-PEG-PLGA NPs has been determined by 
measuring the zeta potential that would aid in determining more about the particle properties and 
its interaction with the biological system. The empty PLGA-PEG-PLGA NPs revealed to have 
negatively charge surface (-2.66mV) as the polymer is affected by the PLGA co-polymer end 
group [98].  
In addition, the cardiotoxicity of empty PLGA-PEG-PLGA NPs have been studied to 
determine if this type of polymers would cause any cardiotoxicity or adverse side effects. To test 
for them, zebrafish model has also been used and the high concentrations of PLGA-PEG-PLGA 
NPs (1 mg/ml & 0.75 mg/ml) showed to have a little toxicity as indicated by the low survival rate 
than the normal control and by the cardiac outputs with low heartbeat, low DA diameter and blood 
flow velocity. While the lowest concentrations (0.5, 0.25, 0.1 and 0.05 mg/ml) showed values close 
to that of the normal control, showing that PLGA-PEG-PLGA NPs has low toxic effects as these 
PLGA-PEG-PLGA NPs have been approved by the US Food and Drug Administration due to their 
excellent biodegradability and because of their ability to improve bioavailability and antitumor 
targeting [100-102].    
Thirdly, the smart nanoparticle PLGA-PEG-PLGA has been loaded with 5mg, 10mg or 
15mg Ponatinib in order to reduce the drug side toxicity especially on the cardiovascular system. 
The loading of the drug was successfully performed, and this was indicated by the change in the 
surface charge of the PLGA-PEG-PLGA NPs from negative (-2.66mV) to positive (12.3, 15.2 and 
16.7mV) charge for 15mg, 10mg and 5mg, respectively through measuring the zeta potential. This 
is because the Ponatinib surface charge is positive (30.86 mV). This phenomenon was also seen 
by Ku et al. (2010), who disclosed the change in the FMSNs surface charge from negative (-22.43 
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mV) to positive (18.93 mV) due to the conjugation of PAMAM of a positive charge and eventually 
the charged change almost to neutral (1.49 mV) revealing an additional modification of PEG [103]. 
Moreover, the HPLC analysis has confirmed the presence of Ponatinib in the PLGA-PEG-PLGA 
NPs particularly in the PLGA-PEG-PLGA NPs loaded with 5mg Ponatinib at 1hr, with a peak at 
1.699 RT and this has been seen at 3hr but the peak was too small to be definitely defined as 
ponatinib. However, this initial burst release of the drug within a short period of time is undesirable 
as it would shorten the drug overall therapeutic duration and toxicity could also be associated in 
case of excessive burst release [104]. Therefore, PLGA-PEG-PLGA NPs loaded with 10mg and 
15mg that did not show any burst release over the period of two days are the better choice for in 
vivo testing.  
Fourthly, before testing for the efficacy of those loaded PLGA-PEG-PLGA NPs with 10 
and 15mg Ponatinib, in reducing the cardiotoxicity and as effective anti-cancer therapy to treat 
CML, their cardiotoxicity has also been determined using the zebrafish embryos. The 
concentration of 1, 0.75, 0.5, 0.25, 0.1, 0.025, 0.05 and 0.01mg/ml of all groups (5, 10 and 15mg) 
had showed a very clear toxicity based on their survival rates which were the lowest and their 
morphology that was similar to the toxicity results of the Ponatinib drug as the embryos were 
deformed with heart edema and abnormal heart structure as well as for the absence of blood flow 
in the PCV and DA. This could be due to the burst release of Ponatinib that has been determined 
to cause cardiotoxicity or could be due to the presence of free Ponatinib in the stock vial of the 
PLGA-PEG-PLGA NPs. However, the lowest concentrations (0.005 and 0.0025mg/ml) had 
showed a better effect but still there was some observed abnormalities in the embryos, thus the 
5mg Ponatinib loaded PLGA-PEG-PLGA NPs were excluded and a lower concentration 
(0.001mg/ml) from 10 and 15mg Ponatinib loaded PLGA-PEG-PLGA NPs has been tested and it 
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has showed the best results with better survival rate, morphology and cardiac output.  
After that, a zebrafish xenograft model has been generated to test for the efficacy of those 
loaded PLGA-PEG-PLGA NPs with 10 and 15mg Ponatinib, in reducing the cardiotoxicity and as 
effective anti-cancer therapy to treat CML.  This was done by transplanting the human K562 cell 
line. This xenograft model has also been successfully generated as indicated by the spread of the 
tumor cells over the period of 6 days post injection and this model was also achieved by previous 
studies. For example, Corkery et.al. (2011) has also used the K562 cells that were stained by the 
CM-Dil dye to give a red fluorescence color. These cells were then transplanted into the zebrafish 
embryos and the embryos were then kept for 1hr at 28°c for a recovery period and this aided in 
enhancing the embryos’ survival rate [105]. However, in this study, the embryos have been 
immediately incubated at 34°c without a recovery period and this might be the reason behind the 
low survival rate of the injected embryos after one day post injection. Pruvot et. al (2011) has also 
showed a successful transplantation of the K562 cell line into the zebrafish embryos [106].   
Finally, the 10mg and 15mg ponatinib loaded PLGA-PEG-PLGA NPs of the concentration 
0.001mg/ml were exposed to the injected zebrafish embryos (2dpf) after half hour after the 
injection. The tumor cells have not been shown to be reduced clearly over the 6 days period after 
injection, this could be due to the long release time of Ponatinib from the PLGA-PEG-PLGA NPs. 
5.1 Limitations and future directions 
Possible limitation for this study includes, its most dependent on zebrafish embryos that 
needed proper care and training for handling and the xenograft model required even a higher level 
of handling as the embryos are injured. The treated groups of the zebrafish embryos with the loaded 
PLGA-PEG-PLGA NPs were only observed till the ethical end point of 7-dpf, thus the effect of 
the loaded PLGA-PEG-PLGA NPs in reducing tumor cells were only observed for a few days 
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despite that Ponatinib release that could happen after few days of the endpoint. For that, 
xenografted embryos need to be observed for a longer period of time e.g., 10-dpf. Also, the lack 
of FTIR< X-ray and DSC studies, the paradox of the presence of burst release at the lowest drug 
concentration cannot be explained. Also, deducting background fluorescence per unit area of the 
fluorescence images would give better quantitative measurements. 
5.2 Conclusion 
 In summary, zebrafish is a good animal model for investigating the cardiotoxicity 
associated with the anti-cancer drugs such as TKIs, to determine the optimum concentration of 
smart nanoparticles with the least side effects and to generate xenograft model of several cancer 
types.  
In this study, PLGA-PEG-PLGA NPs were synthesized to carry the TKIs drugs. These NPs 
have shown to carry Ponatinib drug (10mg and 15mg) for a long period of time, allowing for longer 
circulation in the zebrafish body. The toxicity of two TKIs has also been tested on this animal 
model revealing the optimum concentrations that would not cause cardiotoxicity in the model. The 
lowest concentration of Imatinib and Ponatinib (2.5µM) is the optimum concentration with the 
least cardiotoxicity and better survival rate. Zebrafish animal model was also used for testing the 
cardiotoxicity of a range of different concentrations of loaded and unloaded PLGA-PEG-PLGA 
NPs and the least concentrations showed to be of low toxicity and enhanced survival rate. The 
concentrations 0.1 and 0.05 mg/ml of the unloaded PLGA-PEG-PLGA NPs are the best in term of 
low cardiotoxicity and high survival rate, while 0.001mg/ml concentration of the loaded PLGA-
PEG-PLGA NPs with 10 or 15mg Ponatinib has shown to be the optimum concentration among 
the rest of the concentrations. Lastly, these loaded NPs have been exposed to the successfully 
generated CML xenograft zebrafish model, however, no obvious reduce in the tumor mass was 
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seen indicating the slow release of Ponatinib from PLGA-PEG-PLGA NPs.  
Generally, PLGA-PEG-PLGA NPs could be good candidate for CML treatment, but their 
cellular internalization should be enhanced. This could be achieved by coating and labeling the 
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